Management of nausea and vomiting during treatment with the capsule (CAP) and tablet (TAB) formulations of the PARP inhibitor olaparib

被引：3

作者：

Banerjee, S. ^{[1
]}

Ledermann, J. ^{[2
]}

Matulonis, U. ^{[3
]}

Molife, L. R. ^{[1
]}

Friedlander, M. ^{[4
]}

Fielding, A. ^{[5
]}

Robertson, J. D. ^{[5
]}

Spencer, S. ^{[6
]}

McMurtry, E. ^{[5
]}

Kaye, S. ^{[1
]}

机构：

[1] Royal Marsden Hosp, Drug Dev Unit, Sutton, Surrey, England

[2] UCL, Inst Canc, London, England

[3] Dana Farber Canc Inst, Gynecol Canc Ctr, Boston, MA 02115 USA

[4] Prince Wales Hosp, Dept Clin Oncol, Sydney, NSW, Australia

[5] AstraZeneca, Global Med Dev, Macclesfield, Cheshire, England

[6] AstraZeneca, Dept Stat, Macclesfield, Cheshire, England

来源：

关键词：

D O I：

10.1016/S0959-8049(16)31525-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2759

引用

页码：S550 / S550

页数：1